Loading stock data…
$1.75-0.11 (-5.66%)
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors.
Pyxis Oncology, Inc. in the Healthcare sector is trading at $1.75 with a market capitalization of $273M. Wall Street consensus targets $8.67 (9 analysts), implying a +395.2% move over the next 12 months. The stock is currently near its 52-week low of $1.03, remaining 18.2% below its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the distress zone. Risk note: RSI 12 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 55/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0↓ | $11.04M | $0↓ | $2.82M |
| Gross Profit | — | — | $8.65M | $0↓ | $2.82M |
| Operating Income | -$25.99M↓ | -$24.36M↓ | -$18.30M↑ | -$23.46M↓ | -$19.75M |
| Net Income | -$25.35M↓ | -$23.27M↓ | -$18.11M↑ | -$22.00M↓ | -$18.35M |
Pyxis Oncology, Inc., a clinical stage company, engages in the development of therapeutics to treat solid tumors. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1...